Atom-level backbone engineering preserves peptide function while enhancing stability
He, M.; Cheng, K. F.; Vu, A.; D.T. Torres, M.; Zanos, S.; Mughrabi, I.; de la Fuente-Nunez, C.; Al-Abed, Y.
Show abstract
Peptide therapeutics offer unmatched potency and selectivity but are limited by rapid proteolysis and poor pharmacokinetics. Backbone engineering provides a rational approach to enhance stability while preserving function, yet direct comparisons across strategies remain scarce. Using bradykinin as a model, we systematically evaluated four backbone modifications--D-amino acid substitution, N-methylation, -methylation, and azapeptide incorporation. Each modification produced distinct outcomes in synthesis, conformation, proteolytic stability, and receptor pharmacology. While D- and N-methyl substitutions yielded high stability, they compromised receptor binding and in vivo function. In contrast, the azapeptide analogue maintained native-like affinity and physiological activity while achieving an enhanced stability profile. These findings highlight the need to balance stability and function in peptide design and position azapeptides as an underexplored class with strong therapeutic potential. More broadly, this study establishes a framework for systematic, data-driven peptide design and optimization.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Discovery of CD28-Targeted Small Molecule Inhibitors of T Cell Co-stimulation Using Affinity Selection-Mass Spectrometry (AS-MS) and Ex Vivo Validation 94%
- Development of potent and selective CK1α Molecular Glue Degraders 94%
- A small-molecule oral agonist of the human glucagon-like peptide-1 receptor 93%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Development of esterase-resistant and highly active ghrelin analogs via thiol-ene click chemistry 93%
- AI-Assisted Discovery and Optimization of Small Molecule TREM2 Agonists with Functional Microglial Activity 93%
- TMPRSS2 inhibitor discovery facilitated through an in silico and biochemical screening platform 93%
Similar papers in this journal
- Predicting antiviral resistance mutations in SARS-CoV-2 main protease with computational and experimental screening 91%
- Inhibition of CREB binding and function with a dual-targeting ligand 91%
- Nanomolar, noncovalent antagonism of hedgehog cholesterolysis: exception to the irreversibility rule for protein autoprocessing inhibition. 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.